Program focus
Works on desire, not just blood flow
Reviewed in context with your intake, medications, history, state eligibility, and the clinician's judgment.
Sexual health · bremelanotide
PT-141 — desire and arousal support for men and women.
PT-141 (bremelanotide) is the active ingredient in FDA-approved Vyleesi. Livozo offers a clinician-led, on-demand pathway — reviewed around your history, prescribed only when appropriate, and compounded by a licensed pharmacy partner.
At a glance
What this pathway is built to clarify.
Program focus
Men and women
Reviewed in context with your intake, medications, history, state eligibility, and the clinician's judgment.
Program focus
On-demand (PRN) dosing
Reviewed in context with your intake, medications, history, state eligibility, and the clinician's judgment.
Clinical context
When a clinician may look closer.
Livozo is designed to collect the right context before treatment is considered. These pages describe possible care pathways, not a promise that any medication will be prescribed.
Compounded PT-141 is not FDA-approved and is not interchangeable with Vyleesi. It can raise blood pressure and is not suitable for everyone. A licensed clinician must review your history before prescribing.
- Low libido or low desire
- PDE5 (Viagra/Cialis) non-response
- Arousal difficulty
- Desire concerns alongside other treatment
Care model
What the program can include.
Clinical review
- Confidential medical intake
- Synchronous clinician evaluation
- Patient-specific prescription when appropriate
- Follow-up for response and side effects
Potential options
- Compounded bremelanotide (PT-141) subcutaneous
- PDE5 options when clinically appropriate
- Combination pathways only when a clinician directs
Exact medication, formulation, quantity, refill timing, and pharmacy routing depend on partner agreements, applicable law, and clinical appropriateness.
Next step
Start with eligibility, not checkout pressure.
The right first step is a private intake that can be routed to licensed clinical partners. If the program is not appropriate, the flow should clearly say so before payment or fulfillment.
Check eligibility